PEAR Therapeutics logo

Pear Therapeutics

Pear (Nasdaq: PEAR) discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.

peartherapeutics.com
Boston, MA

CEO: Corey McCann
Arboretum Lead: Tim Petersen

IN THE NEWS
December 6, 2021 in Home Page, News Page, Pear Therapeutics

Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Company

Pear Therapeutics, Inc. (“Pear Therapeutics”), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), recently announced the completion of its business combination with Thimble Point Acquisition…
Read More
November 23, 2021 in News Page, Pear Therapeutics

Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), recently announced that it has received Breakthrough Device Designation from the U.S. Food and…
Read More
August 10, 2021 in News Page, Pear Therapeutics

Pear Therapeutics Announces Formulary Availability for its Three FDA Authorized Prescription Digital Therapeutics at OptumRX

Pear Therapeutics, Inc. today announced formulary availability of its commercial products at OptumRx, Inc., the innovative pharmacy care services business of Optum, Inc. Pear’s commercial products include the Prescription Digital…
Read More
July 28, 2021 in News Page, Pear Therapeutics

Pear Therapeutics Announces Publication of Data Analysis Showing Real-World Cost Impact of ReSET-O®

Pear Therapeutics, Inc., today announced publication of a new analysis demonstrating the real-world cost impact of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of…
Read More